SIRPA and neoplasm: Additionally, several strategies have been proposed and are being intensively explored, for example, anti-CD47 antibody (124–128), anti-SIRPα antibody (129), bi-specific antibodies to CD47 or SIRPα or other molecules (129), SIRPα-related fusion proteins (130), and others (131), to improve therapeutic efficacy during targeting CD47/SIRPα pathway while overcome on-target/off-tumor effects (132, 133).